Electromed vs Sight Sciences
Sight Sciences reported revenue of $77 million in fiscal 2025, about the same as Electromed's $74 million in fiscal 2026. Electromed's revenue grew 15.3% in its latest year, and Sight Sciences' fell 3.1%. Electromed had an operating margin of 18.8%, against -48.0% at Sight Sciences. Free cash flow was $8 million at Electromed and −$30 million at Sight Sciences. Their fiscal years end in different months (June 30 and December 31), so the periods don't line up exactly.
Side by side
| Electromed | Sight Sciences | |
|---|---|---|
| Latest fiscal year | FY2026, Jun 30, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $74M | $77M |
| Revenue growth | 15.3% | −3.1% |
| Revenue growth a year, last 5 years | 15.6% | 22.9% |
| Gross margin | 78.5% | 86.2% |
| Operating margin | 18.8% | −48.0% |
| Net margin | 15.3% | −49.7% |
| Free cash flow | $8M | −$30M |
| Free cash flow margin | 11.4% | −38.7% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $4M | $0M |
| Change in diluted share count | −2.5% | 4.0% |
| Last close | $23.26 | $10.62 |
| P/E at the last close | 16.9× | — |
| Insider trades, last 12 months | sold $2.2 million | bought $184,799, sold $2.3 million |
| Piotroski F-score | — | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ElectromedSight Sciences
Operating margin
Percent of revenue
ElectromedSight Sciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ElectromedSight Sciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Electromed and Sight Sciences pages.